• EMA grants orphan drug designation to AlloVir’s Viralym-M pharmaceutical-business-review
    March 31, 2020
    AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, announced it has been granted Orphan Drug Designation from the European Medicines Agency (EMA) for Viralym-M (ALVR105).
PharmaSources Customer Service